Healthcare Jul 13, 2021 08:47 PM (GMT+8) · EqualOcean
The first indication clinical trial of c-4-29 cell preparation developed by Chongqing precision Biotechnology Co., Ltd. (precision Biology) was approved by the drug evaluation center of State Drug Administration on December 10, 2020, and the second indication clinical trial application was accepted by CDE on July 8, 2021, realizing the breakthrough of car-t cell therapy for solid tumor. The company's CD70 target is the first in China, and the product c-4-29 cell preparation under research is used for the treatment of patients with relapsed / refractory multiple myeloma or advanced / metastatic renal cell carcinoma aged 18 years or above.
Related companies: